July 2020 Industry Spotlight
Founded in 2015 and located in the bwtech @UMBC Technology Center, FZata, Inc. is an antibody technology company dedicated to developing antibody drugs and oral biotherapeutics. As a University of Maryland Baltimore (UMB) spin-out company, FZata not only has licensed IP from UMB, but also develops its own proprietary technologies. From its cutting-edge, multi-specific antibody and yeast biotherapy platforms, FZata has developed a pipeline of drugs that enable physicians to treat various diseases. FZata’s innovative projects have earned it numerous NIH grants valued in the tens of millions of dollars.
Maryland Incubator Company of the Year (ICOY) Awards recognize the achievements of current and past incubator companies in the state. FZata was honored as a 2017 Maryland Incubator Company of the Year: Best Life Sciences Company. EAGB recently asked FZata’s leader, Dr. Zhiyong Yang, about her company’s location in Greater Baltimore:
“As a top biotech cluster in the US, Greater Baltimore provides great and sometimes very unique opportunities for biotech startups like us. From the hundreds of life science companies, universities, and federal labs in Maryland and the neighboring Capital area, it’s easy to find ideal strategic partners. From the top notch academic and research institutions, it’s easy to spot many ideal talents. The Maryland Biotechnology Investment Incentive Tax Credit helped us attract venture capital. TEDCO and our incubator provide us with countless support physically, financially and mentally; and the numerous great events – such as Emerging Company Roundtables and CONNECTpreneur – not only help build a closely-intertwined network in this area, but personally cultured my transition from a scientist to an entrepreneur. I am really thankful for all the resources provided from this great area.”
-Zhiyong Yang, cofounder and CEO, FZata, Inc.
Access the full EAGB July 2020 Region On Point newsletter here.
To return to the top of this page: